Recent trends in cost-related medication nonadherence among stroke survivors in the United States

Annals of Neurology

Volumn 73, Issue 2, 2013, Pages 180-188

  Levine, Deborah A ^a,b   Morgenstern, Lewis B ^a,c   Langa, Kenneth M ^a,b,d   Piette, John D ^a,b   Rogers, Mary A M ^a   Karve, Sudeep J ^e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVOR; TREATMENT REFUSAL; UNITED STATES;

AGE DISTRIBUTION; AGED; COMORBIDITY; DRUG COSTS; FEMALE; FINANCING, PERSONAL; HEALTH SURVEYS; HUMANS; INSURANCE, HEALTH; MALE; MEDICARE PART D; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; SOCIOECONOMIC FACTORS; STROKE; SURVIVORS; UNITED STATES;

EID: 84875443968     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23823     Document Type: Article

References (49)

1. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care 2004; 42: 626-634.
2. Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Med Care 2010; 48: 87-94.
3. Rahimi AR, Spertus JA, Reid KJ, et al. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA 2007; 297: 1063-1072.
4. McHorney CA, Spain CV,. Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008. Health Expect 2011; 14: 307-320.
5. Piette JD, Rosland AM, Silveira MJ, et al. Medication cost problems among chronically ill adults in the US: did the financial crisis make a bad situation even worse? Patient Prefer Adherence 2011; 5: 187-194.
6. Love J,. The economic slowdown's impact on middle-aged and older Americans. Washington, DC: AARP, May 2008. Available at: http://assets.aarp.org/ rgcenter/econ/economy-survey.pdf Accessed December 16, 2011.
7. Collins SR, Doty MM, Robertson R, Garber T,. Help on the horizon. How the recession has left millions of workers without health insurance, and how health reform will bring relief. Findings from the Commonwealth Fund Biennial Health Insurance Survey of 2010. March 2011. Available at: http://www.commonwealthfund. org/media/Files/Publications/Fund%20Report/2011/Mar/1486-Collins-help-on-the- horizon-2010-biennial-survey-report-FINAL-v2.pdf Accessed December 16, 2011.
8. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
9. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-944.
10. Samsa GP, Bian J, Lipscomb J, Matchar DB,. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999; 30: 338-349.
11. Collaborative overview of randomised trials of antiplatelet therapy-I,: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
12. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
13. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
14. Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
15. Hankey GJ, Warlow CP,. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999; 354: 1457-1463.
16. Ostwald SK, Wasserman J, Davis S,. Medications, comorbidities, and medical complications in stroke survivors: the CAReS study. Rehabil Nurs 2006; 31: 10-14.
17. Banthin JS, Bernard DM,. Changes in financial burdens for health care: national estimates for the population younger than 65 years, 1996 to 2003. JAMA 2006; 296: 2712-2719.
18. The National Center for Health Statistics, National Health Interview Survey. Available at: http://www.cdc.gov/nchs/nhis.htm Accessed December 16, 2011.
19. Piette JD, Heisler M, Wagner TH,. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy in response to financial pressures. J Clin Epidemiol 2006; 59: 739-746.
20. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004; 291: 2344-2350.
21. Roth GA, Morden NE, Zhou W, et al. Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent. Circ Cardiovasc Qual Outcomes 2012; 5: 103-112.
22. Levine DA, Kiefe CI, Houston TK, et al. Younger stroke survivors have reduced access to physician care and medications: National Health Interview Survey from years 1998 to 2002. Arch Neurol 2007; 64: 37-42.
23. Medicare.gov. The official US government site for people with Medicare. Available at: http://www.medicare.gov Accessed August 31, 2012.
24. Gelberg L, Andersen RM, Leake BD,. The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people. Health Serv Res 2000; 34: 1273-1302.
25. Goldstein LB, Samsa GP, Matchar DB, Horner RD,. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004; 35: 1941-1945.
26. Neuman P, Strollo MK, Guterman S, et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff (Millwood) 2007; 26: w630-w643.
27. Pedan A, Lu J, Varasteh LT,. Assessment of drug consumption patterns for Medicare Part D patients. Am J Manag Care 2009; 15: 323-327.
28. Yin W, Basu A, Zhang JX, et al. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med 2008; 148: 169-177.
29. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008; 299: 1922-1928.
30. Schondelmeyer SW, Purvis, L,. Rx price watch report, March 2012: trends in retail prices of prescription drugs widely used by Medicare beneficiaries 2005 to 2009. Available at: http://www.aarp.org/ppi Accessed March 13, 2012.
31. Skarupski KA, de Leon CF, Barnes LL, Evans DA,. Medicare part D enrollment in a biracial community-based population of older adults. Gerontologist 2009; 49: 828-838.
32. Schoen C, Doty MM, Robertson RH, Collins SR,. Affordable Care Act reforms could reduce the number of underinsured US adults by 70 percent. Health Aff (Millwood) 2011; 30: 1762-1771.
33. Ngo-Metzger Q, Sorkin DH, Billimek J, et al. The effects of financial pressures on adherence and glucose control among racial/ethnically diverse patients with diabetes. J Gen Intern Med 2012; 27: 432-437.
34. Menon BK, Frankel MR, Liang L, et al. Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients (MATCH) clinical trial results. Stroke 2010; 41: 2094-2097.
35. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5: 615-621.
36. Ovbiagele B, Schwamm LH, Smith EE, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke 2010; 41: 1508-1513.
37. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305: 1677-1684.
38. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
39. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
40. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
41. Gage BF,. Can we rely on RE-LY? N Engl J Med 2009; 361: 1200-1202.
42. Gage BF,. Cost of dabigatran for atrial fibrillation. BMJ 2011; 343: d6980.
43. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-2809.
44. Colivicchi F, Bassi A, Santini M, Caltagirone C,. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 2652-2657.
45. Khan NA, Yun L, Humphries K, Kapral M,. Antihypertensive drug use and adherence after stroke: are there sex differences? Stroke 2010; 41: 1445-1449.
46. Simpson CF, Boyd CM, Carlson MC, et al. Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc 2004; 52: 123-127.
47. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol 2004; 160: 1152-1158.
48. Ho PM, Bryson CL, Rumsfeld JS,. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.
49. Pit SW, Byles JE, Cockburn J,. Accuracy of telephone self-report of drug use in older people and agreement with pharmaceutical claims data. Drugs Aging 2008; 25: 71-80.